000230574 001__ 230574
000230574 005__ 20181203024816.0
000230574 0247_ $$2doi$$a10.1055/s-0042-121491
000230574 022__ $$a2194-9379
000230574 02470 $$2ISI$$a000407004300002
000230574 037__ $$aARTICLE
000230574 245__ $$aIn vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I).
000230574 260__ $$bGeorg Thieme Verlag Kg$$c2017$$aStuttgart
000230574 269__ $$a2017
000230574 300__ $$a4
000230574 336__ $$aJournal Articles
000230574 520__ $$aThe aim of the present investigation was to develop matrix tablet formulations for the in vitro controlled release of 2 new tuberculocidal adamantane aminoethers (compounds I and II), congeneric to the adamantane derivative SQ109 , which is in final clinical trials, using carefully selected excipients, such as polyvinylpyrrolidone, sodium alginate and lactose. The tablets were prepared using the direct compression method and dissolution experiments were conducted using the US Pharmacopoeia type II apparatus (paddle method) in gastric and intestinal fluids. The results confirm that both analogues, albeit more lipophilic than SQ109, showed satisfactory in vitro release characteristics from solid pharmaceutical formulations. In conclusion, these formulations merit further assessment by conducting in the future bioavailability in vivo studies.
000230574 6531_ $$a1
000230574 6531_ $$a3-Bis[4-(2-morpholinoethoxy)phenyl]adamantane
000230574 6531_ $$a2
000230574 6531_ $$a2-Bis[4-(2-morpholinoethoxy)phenyl]adamantane
000230574 6531_ $$aantituberculars
000230574 6531_ $$adrug delivery
000230574 700__ $$uUniv Athens, Div Pharmaceut Technol, Sch Hlth Sci, Dept Pharm, Panepistimioupoli Zografou, Athens 15784, Greece$$aVlachou, Marilena
000230574 700__ $$aSiamidi, Angeliki
000230574 700__ $$uUniv Athens, Div Pharmaceut Technol, Sch Hlth Sci, Dept Pharm, Panepistimioupoli Zografou, Athens 15784, Greece$$aDiamantidi, Evanthia
000230574 700__ $$uUniv Athens, Div Pharmaceut Technol, Sch Hlth Sci, Dept Pharm, Panepistimioupoli Zografou, Athens 15784, Greece$$aIliopoulou, Alexandra
000230574 700__ $$uUniv Athens, Div Pharmaceut Chem, Sch Hlth Sci, Dept Pharm, Athens, Greece$$aPapanastasiou, Ioannis
000230574 700__ $$uUniv Athens, Div Pharmaceut Chem, Sch Hlth Sci, Dept Pharm, Athens, Greece$$aIoannidou, V.
000230574 700__ $$uUniv Athens, Div Pharmaceut Chem, Sch Hlth Sci, Dept Pharm, Athens, Greece$$aKourbeli, Violeta
000230574 700__ $$uUniv Athens, Div Pharmaceut Chem, Sch Hlth Sci, Dept Pharm, Athens, Greece$$aFoscolos, Angeliki-Sofia
000230574 700__ $$uEcole Polytech Fed Lausanne, Global Hlth Inst, Lausanne, Switzerland$$aVocat, Anthony
000230574 700__ $$0243892$$g177247$$uEcole Polytech Fed Lausanne, Global Hlth Inst, Lausanne, Switzerland$$aCole, Stewart T.
000230574 700__ $$uUniv Athens, Div Pharmaceut Technol, Sch Hlth Sci, Dept Pharm, Panepistimioupoli Zografou, Athens 15784, Greece$$aKaralis, Vangelis
000230574 700__ $$aKellici, Tahsin
000230574 700__ $$aMavromoustakos, Thomas
000230574 773__ $$j67$$tDrug Research$$k8$$q447-450
000230574 909C0 $$xU11742$$0252302$$pUPCOL
000230574 909CO $$pSV$$particle$$ooai:infoscience.tind.io:230574
000230574 917Z8 $$x282550
000230574 937__ $$aEPFL-ARTICLE-230574
000230574 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000230574 980__ $$aARTICLE